An observational study in Placenta Accreta, Placenta Percreta and Placenta Increta, sponsored by Ain Shams Maternity Hospital. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-10-09.
Sponsored by Ain Shams Maternity Hospital · Observational
Cell free fetal DNA might predict abnormal placental invasion
This study aims to evaluate whether measurement of cell-free fetal DNA in the maternal plasma can be predictive of abnormal invasion in cases of placenta previa.
147 studies on the registry are indexed under Placenta Accreta; 39 are open to participants now.
This study's planned enrollment of 50 is below the median of 84 across 79 observational studies indexed under Placenta Accreta.
Browse Placenta Accreta studies →Ain Shams Maternity Hospital is the lead sponsor of 135 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study group (1): 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
Exclusion criteria:
Patients taking a tocolytic agent or those with uterine bleeding at or after blood sampling.
Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
Diagnostic Test: Maternal plasma cell free fetal DNA levels
Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
Diagnostic Test: Maternal plasma cell free fetal DNA levels
Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
Predictive value of maternal plasma cell free DNA
Prediction of abnormal placental invasion in cases of placenta previa. Primary aim: Is to evaluate whether measurement of cell-free fetal DNA in the maternal plasma can be predictive of abnormal placental invasion in cases of placenta previa. Secondary aim: To decrease maternal morbidity and mortality by early prenatal diagnosis of abnormal placental invasion in placenta previa
Time frame: 4 months
maternal morbidity
maternal morbidity
Time frame: 4 months
This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ain Shams Maternity Hospital